Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

entities : Astrazeneca plc    crawled date : 2022 - 05 - 05    save search

Global Asthma and COPD Drugs Market Report to 2030 - Opportunity Analysis and Industry Forecasts
Published: 2022-05-05 (Crawled : 18:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510 twitter stocktwits trandingview |
Health Technology
| | O: 0.18% H: 0.46% C: 0.46%
SNYNF | News | $92.7 -2.18% 600K twitter stocktwits trandingview |
Health Technology
| | O: 1.98% H: 0.0% C: -2.72%
AZNCF | News | $138.24 -4.19% 800 twitter stocktwits trandingview |
Health Technology
| | O: -0.86% H: 1.57% C: -0.42%
NVS | $94.36 1.93% 0.0% 2.3M twitter stocktwits trandingview |
Health Technology
| | O: -0.39% H: 0.15% C: -1.07%
GSK | News | $39.75 1.22% 0.0% 1.6M twitter stocktwits trandingview |
Health Technology
| | O: -0.98% H: 0.0% C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M twitter stocktwits trandingview |
Health Technology
| | O: -0.73% H: 0.12% C: -1.61%
SNY | News | $46.32 2.05% 2.01% 3.3M twitter stocktwits trandingview |
Health Technology
| | O: 0.66% H: 0.0% C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M twitter stocktwits trandingview |
Health Technology
| | O: -1.35% H: 0.4% C: -1.2%

report market drug
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
Published: 2022-05-05 (Crawled : 12:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M twitter stocktwits trandingview |
Health Technology
| | O: -1.35% H: 0.4% C: -1.2%

enhertu approved cancer breast cancer her2- her2 metastatic breast cancer
ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
Published: 2022-05-05 (Crawled : 10:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M twitter stocktwits trandingview |
Health Technology
| | O: -1.35% H: 0.4% C: -1.2%

enhertu approved positive cancer breast cancer her2- her2 metastatic breast cancer
Gainers vs Losers
67% 33%

Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M twitter stocktwits trandingview |
Finance

EGOX | $0.0515 43.06% 30.1% 330M twitter stocktwits trandingview |

OLB 4 | $0.33 -14.95% 25.53% 840K twitter stocktwits trandingview |
Technology Services

NVFY | $2.77 31.28% 23.83% 33M twitter stocktwits trandingview |
Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M twitter stocktwits trandingview |
Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M twitter stocktwits trandingview |
Distribution Services

INSG | $3.03 25.21% 20.13% 330K twitter stocktwits trandingview |
Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K twitter stocktwits trandingview |
Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M twitter stocktwits trandingview |

ASNS | $0.828 21.75% 17.86% 18K twitter stocktwits trandingview |


Your saved searches
Save your searches and get alerts when important news are released.